Is tirzepatide a better cost-effective weight loss option than semaglutide for obstructive sleep apnea?
The question asks whether tirzepatide is a better cost-effective weight loss option than semaglutide specifically for people with obstructive sleep apnea (OSA). Both drugs are GLP-1 receptor agonists that help with weight loss, which can improve OSA. A 2025 cost-effectiveness study using data from the SURMOUNT-5 trial compared tirzepatide and semaglutide in people with obesity or overweight, including those at risk for OSA. The study found tirzepatide was cost-effective compared to semaglutide from a US societal perspective 59. However, no study has directly compared the cost-effectiveness of these two drugs specifically for treating OSA.
What the research says
A 2025 patient-level simulation modeling study evaluated the cost-effectiveness of tirzepatide at its maximum tolerated dose (MTD) versus semaglutide MTD, both combined with diet and exercise, in people with obesity (BMI ≥30) or overweight (BMI ≥27 with at least one obesity-related complication) 59. The study used data from the head-to-head SURMOUNT-5 trial and modeled long-term outcomes including the risk of developing OSA 59. From a US societal perspective, tirzepatide was found to be cost-effective compared to semaglutide, with incremental cost-effectiveness ratios (ICERs) below common willingness-to-pay thresholds 59. The analysis accounted for weight, blood pressure, cholesterol, and other factors that affect health costs and quality of life 59.
A separate network meta-analysis of 34 trials in OSA patients found that GLP-1 receptor agonists like liraglutide (a similar drug) reduced BMI and HbA1c, but the study did not directly compare tirzepatide and semaglutide for cost or effectiveness in OSA 3. That analysis showed liraglutide plus CPAP led to the greatest BMI reduction, but CPAP alone was best for improving the apnea-hypopnea index (AHI), a key measure of OSA severity 3.
While tirzepatide appears cost-effective for weight loss in a broad population that includes people at risk for OSA, there is no direct evidence comparing its cost-effectiveness to semaglutide specifically for treating established OSA. The available studies focus on weight loss and metabolic outcomes, not on OSA-specific endpoints like AHI or sleepiness scores 359.
What to ask your doctor
- Given my weight and OSA severity, would tirzepatide or semaglutide be more appropriate for me?
- How do the costs of tirzepatide and semaglutide compare with my insurance coverage?
- Should I consider combining a GLP-1 medication with CPAP therapy for better OSA outcomes?
- What are the expected weight loss and potential improvements in my sleep apnea with each medication?
- Are there any long-term studies comparing these drugs specifically for OSA treatment?
This question is drawn from common patient questions about Nutrition & Obesity Medicine and answered using cited medical research. We do not provide individualized advice.